AzTrials
AzTrials

Virtual RealityNCT07580352

Assessing the Feasibility of Using Virtual Reality Experiences in Older Adults

A study testing Feasibility of using VR in people with Virtual Reality and Bucket List, run by Stanford University at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

To assess the feasibility of using computer-generated VR (CG-VR) and film-based VR (FB-VR) in seriously ill older adults Read more about this study

Who is it for?
Ages 65 months and older
Conditions the study is for
Virtual Reality, Bucket List, Serious Illness
What is being tested?
Feasibility of using VR
Could I receive a placebo?
No, everyone receives an active treatment
How many people
52 participants
Where
1 siteUnited States
Study dates
1 Apr 2024to 1 Feb 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 65 months and older
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

None listed.

Who cannot join

  • -

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Stanford University

    Palo Alto, California, 94304

Other trials in United States

About this study

To assess the feasibility of using computer-generated VR (CG-VR) and film-based VR (FB-VR) in seriously ill older adults

Read the detailed description

Background and Significance

Seriously ill older adults frequently harbor unfulfilled end-of-life aspirations, commonly referred to as "bucket list" experiences. Advanced illness, functional decline, and the constraints of institutional living typically render travel and other real world experiences largely unattainable for this population. Virtual reality (VR) technology, now widely commercially available, may offer an accessible means of delivering immersive surrogate experiences at the bedside. However, the feasibility of VR engagement among seriously ill nursing home residents - including their capacity to tolerate head-mounted display use, sustain attention during immersion, and derive meaningful benefit - has not been adequately established. The present study seeks to address this gap.

Specific Aims:

  1. To determine the feasibility of administering immersive VR experiences to seriously ill older adult nursing home residents using a commercially available head-mounted display.
  2. To compare participant ability to tolerate two distinct VR delivery modalities: computer-generated virtual reality (CG-VR) and film-based virtual reality (FB-VR).
  3. To explore, through qualitative inquiry, participant perceptions of VR as a vehicle for fulfilling personally meaningful experiences (virtual bucket-listing).

Study Design

This is a feasibility study employing a randomized, two-arm parallel-group design with an optional crossover component and embedded qualitative interviews.

Study Population: Seriously ill older adult residents of the participating nursing home facility.

Study Procedures

Following written informed consent, each participant will be invited to articulate a personal bucket list. Participants who identify one or more bucket list items will be randomly assigned in a 1:1 ratio to one of two arms:

  • Arm A: A three-minute immersive waterfall experience delivered via CG-VR.
  • Arm B: A three-minute immersive waterfall experience delivered via FB-VR. All VR content will be delivered using the Meta Quest Pro head-mounted display. Following the initial experience, participants will be offered the option to engage in a second VR session - either the alternate modality (CG-VR or FB-VR) or an alternative VR environment of personal significance to the participant.

Outcome Measures:

Primary outcomes (feasibility): Consent, completion of the assigned VR experience, and adverse events (including cybersickness, agitation, or discomfort).

Secondary outcomes:

  • Change in symptom burden as measured by pre- and post-experience scores on the Edmonton Symptom Assessment System-Revised (ESAS-r).
  • Participant-reported relaxation ratings obtained immediately following the VR experience.
  • Qualitative data derived from post-experience semi-structured interviews for thematic analysis.

Risks and Anticipated Benefits:

Risks are anticipated to be minimal and primarily limited to transient cybersickness, mild disorientation, or emotional response to the experiential content. Participants may benefit from symptom relief, relaxation, and engagement with personally meaningful imagery, although direct benefit is not assured. Findings will inform the design of subsequent efficacy trials evaluating VR as a palliative intervention.

Statistical Considerations:

Given that this is a feasibility pilot study, there is no hypothesis testing and the study is not powered to detect efficacy.Descriptive statistics will be employed to characterize feasibility metrics and outcome distributions.

Being tested
Feasibility of using VR

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Feasibility of using VROther

    Commercially available Meta Quest Pro was used to show a waterfalls virtually to the participants in one of two renderings-- computer generated waterfalls or a film-based waterfalls. Both types of renderings are viewed by the exact same equipment and headset.

Study groups in NCT07580352
Study groupRoleWhat they receive
Computer-generated VR waterfallsActive comparatorThis is a computer-generated VR waterfalls
Receives: Other: Feasibility of using VR
Film-based VR waterfallsActive comparatorThis is a film-based VR waterfalls
Receives: Other: Feasibility of using VR

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Edmonton Symptom Assessment Scale (ESASr)

    ESAS-r assessed nine common symptoms (Pain, Fatigue, Nausea, Depression, Anxiety, Drowsiness, Shortness of Breath, Appetite, and Wellbeing) on 0-10 scales. (cite) A sleep item was also included.

    Measured: Baseline

  2. Relaxation scale

    Relaxation was assessed with a single item (0 = not relaxed at all; 10 = extremely relaxed)

    Measured: Immediately before and after the 3-minute VR exposure.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 May 2026
  2. Study start1 Apr 2024
  3. Primary completion1 Feb 2025
  4. Study completion1 Feb 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Supportive care
Allocation
Randomised
Intervention model
Parallel groups
Model description
CG-VR or FB-VR
Masking
Single blind
Who is masked
Participant
Enrolment
52 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07580352
Sponsor's protocol ID
67522
Status last verified
May 2026
First submitted
5 May 2026
Last updated
15 May 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: Will not be available as participants are vulnerable and did not wish to share.

Questions about this trial

What is this clinical trial studying?

A study testing Feasibility of using VR in people with Virtual Reality and Bucket List, run by Stanford University at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 0 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Edmonton Symptom Assessment Scale (ESASr) (time frame: Baseline). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 May 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in